fda warning letters compounded semaglutide tirzepatide 2024 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA issued 25 warning letters
Description
On a GLP-1, appetite crashes and muscle can go with it
GLP-1s offer treatment for diabetes, obesity, heart disease and morebut there are caveats
A 2025 meta-analysis in JAMA Psychiatry looked at GLP-1 receptor agonists and mental health outcomes across multiple studies
Los pacientes que utilizan este medicamento han reportado mejoras en su control glucmico y una reduccin en el riesgo de complicaciones asociadas a la diabetes, como enfermedades cardiovasculares
Those who are managing insulin resistance or pre-diabetes
It is becoming one of the biggest growth opportunities in pharmaceutical history, with analysts projecting the market to exceed hundreds of billions of dollars over the coming decade
